The Challenge
Mario was receiving FOLFIRINOX but was uncertain about the value of his biomarker results, when to consider clinical trials, and what options might come next. He was also coping with cancer-related fatigue and a lack of clarity in his care plan.
Our Impact
Cancer Commons confirmed his current treatment was appropriate, explained the significance of his KRAS G12R mutation and other biomarkers, advised pausing trial enrollment until FOLFIRINOX was no longer effective, and recommended a second opinion at a top cancer center in the region to help secure future trial access. Supportive care and integrative oncology resources were also shared.
The Outcome
Mario gained clear validation of his treatment plan, a roadmap for next steps, and practical resources for whole-person support. Grateful for the clarity and guidance, he made a donation to help extend services to others.
